Current cancer stem cell biomarkers in laryngeal cancer

Year 2017, Volume: 3 Issue: 3, 200 - 206, 04.11.2017

Omer Faruk Karatas , Neslisah Barlak , Huseyin Sahin Hatice Aydin

https://doi.org/10.18621/eurj.310778

Cited By: 1

Abstract

Larynx
cancer (LCa), being an aggressive malignancy, is the second most commonly
diagnosed malignant type of head and neck squamous cell carcinoma worldwide.
Although there have been significant improvements in the detection and
diagnosis of LCa in the last decades, it is still one of the considerable
causes of cancer deaths and an urgent need for identification of novel
biomarkers with diagnostic and prognostic significance still remains. The
cancer stem cells (CSCs) resemble normal stem cells in terms of biological
features and are considered to play critical roles in biological aggressiveness
of tumors. Accumulating evidences have proven the existence of CSCs in various
tumors including LCa and they are considered as driving force for tumor
relapse, metastasis, and chemo-radioresistance. Comprehensive identification
and characterization of the CSCs is of paramount importance for their further
characterization to develop more effective and targeted therapeutic strategies
against cancer. Here, we reviewed and summarized the most current literature to
provide an insight into the functions and roles of current CSCs biomarkers in
human LCa. We believe that this review will contribute to the knowledge of
scientists especially working with LCa CSCs and will help understanding the
significance of CSCs biomarkers implicated in LCa pathogenesis.

Keywords

Larynx cancer, cancer stem cell, biomarker

References

• [1] Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 2008;41:673-95, v.
• [2] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017;67:7-30.
• [3] Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
• [4] Li F, Tiede B, Massagué J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res 2007;17:3-14.
• [5] Masters JR, Kane C, Yamamoto H, Ahmed A. Prostate cancer stem cell therapy: hype or hope? Prostate Cancer Prostatic Dis 2008;11:316-9.
• [6] Hao J, Zhao S, Zhang Y, Zhao Z, Ye R, Wen J, et al. Emerging role of microRNAs in cancer and cancer stem cells. J Cell Biochem 2014;115:605-10.
• [7] Leal JA, Lleonart ME. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 2013;338:174-83.
• [8] Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
• [9] Huang EH, Wicha MS. Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med 2008;14:503-9.
• [10] Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006;86:1203-7.
• [11] Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012;44:2144-51.
• [12] Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
• [13] Zhou L, Wei X, Cheng L, Tian J, Jiang JJ. CD133, one of the markers of cancer stem cells in Hep-2 cell line. Laryngoscope. 2007;117:455-60.
• [14] Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013;15:338-44.
• [15] Lawson DA, Witte ON. Stem cells in prostate cancer initiation and progression. J Clin Invest 2007;117:2044-50.
• [16] Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90:5013-21.
• [17] Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 2009;18:1127-34.
• [18] Wang J, Wu Y, Gao W, Li F, Bo Y, Zhu M, et al. Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer 2017;8:497-506.
• [19] Wei XD, Zhou L, Cheng L, Tian J, Jiang JJ, Maccallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head Neck 2009;31:94-101.
• [20] Schneider M, Huber J, Hadaschik B, Siegers GM, Fiebig HH, Schuler J. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer 2012;12:96.
• [21] Suer I, Karatas OF, Yuceturk B, Yilmaz M, Guven G, Buge O, et al. Characterization of stem-like cells directly isolated from freshly resected laryngeal squamous cell carcinoma specimens. Curr Stem Cell Res Ther 2014;9:347-53.
• [22] Wu CP, Zhou L, Xie M, Tao L, Zhang M, Tian J. [Isolation and in vitro characterization of CD133(+) side population cells from laryngeal cancer cell line]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;46:752-7. [Article in Chinese]
• [23] Wu CP, Zhou L, Xie M, Tao L, Zhang M, Tian J. [Isolation and in vivo tumorigenicity assay of CD133+ side population cells from laryngeal cancer cell line]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2012;47:223-27. [Article in Chinese]
• [24] Zhang SY, Lu ZM, Luo XN, Chen LS, Ge PJ, Song XH, et al. Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment. PLoS One 2013;8:e60157.
• [25] Yu L, Zhou L, Wu S, Gong X, Feng Z, Ma L, et al. Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma. World J Surg Oncol 2014;12:118.
• [26] Wei X, He J, Gao J, Chen J, Wang J. [Investigation of self-renewal mechanism about CD133+ cancer stem cells in human laryngeal carcinoma Hep-2 cell line]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2014;28:1636-41. [Article in Chinese]
• [27] Chen XH, Bao YY, Zhou SH, Wang QY, Wei Y, Fan J. Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells. Mol Med Rep 2013;8:1695-700.
• [28] Wei XD, He J, Gao JX, Wang JY, Ma BJ, Chen J. [Investigation on biological characteristics of CD133+ cancer stem cells in human laryngeal carcinoma Hep-2 cell line]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2013;48:578-3. [Article in Chinese]
• [29] Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD. A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 2010;289:151-60.
• [30] Zhang H, Yu T, Wen L, Wang H, Fei D, Jin C. Curcumin enhances the effectiveness of cisplatin by suppressing CD133(+) cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med 2013;6:1317-21.
• [31] Qi X, Yu D, Jia B, Jin C, Liu X, Zhao X, et al. Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles. Tumour Biol 2016;37:2209-17.
• [32] Basakran NS. CD44 as a potential diagnostic tumor marker. Saudi Med J 2015;36:273-9.
• [33] Senbanjo LT, Chellaiah MA. CD44: A Multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol 2017;5:18.
• [34] Yu D, Jin CS, Zhao Y, Xu CB. [Preliminary study on biological characteristics of CD(44)(+) stem cells in human laryngeal carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;43:845-50. [Article in Chinese]
• [35] Lu S, Tian J, Lv Z, Wang H, Bai X, Liu W, et al. The probable role of tumor stem cells for lymph node metastasis in supraglottic carcinoma. Pathol Oncol Res 2011;17:33-8.
• [36] Kokko LL, Hurme S, Maula SM, Alanen K, Grénman R, Kinnunen I, et al. Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 2011;47:510-6.
• [37] Trapasso S, Garozzo A, Belfiore A, Allegra E. Evaluation of the CD44 isoform v-6 (sCD44var, v6) in the saliva of patients with laryngeal carcinoma and its prognostic role. Cancer Biomark 2016;16:275-80.
• [38] Zamulaeva IA, Matchuk ON, Selivanova EI, Andreev VG, Lipunov NM, Makarenko SA, et al. [Increase in the number of cancer stem cells after exposure to low-LET radiation]. Radiats Biol Radioecol 2014;54:256-64. [Article in Russian]
• [39] de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010;16:5329-38.
• [40] Sim MW, Grogan PT, Subramanian C, Bradford CR, Carey TE, Forrest ML, et al. Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells. Laryngoscope 2016;126:E184-90.
• [41] Masuko K, Okazaki S, Satoh M, Tanaka G, Ikeda T, Torii R, et al. Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS One 2012;7:e29728.
• [42] Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008;283:17969-78.
• [43] Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011;3:230-8.
• [44] Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-98.
• [45] Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003;6:1162-8.
• [46] Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 2009;27:40-8.
• [47] Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene 2012;31:2270-82.
• [48] Karatas OF, Yuceturk B, Suer I, Yilmaz M, Cansiz H, Solak M, et al. Role of miR-145 in human laryngeal squamous cell carcinoma. Head Neck 2016;38:260-6.
• [49] Yang N, Hui L, Wang Y, Yang H, Jiang X. Overexpression of SOX2 promotes migration, invasion, and epithelial-mesenchymal transition through the Wnt/β-catenin pathway in laryngeal cancer Hep-2 cells. Tumour Biol 2014;35:7965-73.
• [50] Tang XB, Shen XH, Li L, Zhang YF, Chen GQ. SOX2 overexpression correlates with poor prognosis in laryngeal squamous cell carcinoma. Auris Nasus Larynx 2013;40:481-6.
• [51] Wu CP, Du HD, Gong HL, Li DW, Tao L, Tian J, et al. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction. Int J Oncol 2014;44:1652-60.
• [52] Chen H, Zhou L, Dou T, Wan G, Tang H, Tian J. BMI1'S maintenance of the proliferative capacity of laryngeal cancer stem cells. Head Neck 2011;33:1115-25.
• [53] Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38.
• [54] Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002;415:922-6.
• [55] Yu D, Liu Y, Yang J, Jin C, Zhao X, Cheng J, et al. Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma. Cell Biochem Biophys 2015;71:261-9.
• [56] Chen H, Zhou L, Wan G, Dou T, Tian J. BMI1 promotes the progression of laryngeal squamous cell carcinoma. Oral Oncol 2011;47:472-81.
• [57] Wei X, He J, Wang J, Yang X, Ma B. Bmi-1 is essential for the oncogenic potential in CD133(+) human laryngeal cancer cells. Tumour Biol 2015;36:8931-42.
• [58] Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-25.
• [59] Shen B, Dong P, Li D, Gao S. Expression and function of ABCG2 in head and neck squamous cell carcinoma and cell lines. Exp Ther Med 2011;2:1151-7.
• [60] Yu D, Jin C, Liu Y, Yang J, Zhao Y, Wang H, et al. Clinical implications of cancer stem cell-like side population cells in human laryngeal cancer. Tumour Biol 2013;34:3603-10.
• [61] Shen B, Li D, Dong P, Gao S. Expression of ABC transporters is an unfavorable prognostic factor in laryngeal squamous cell carcinoma. Ann Otol Rhinol Laryngol 2011;120:820-7.
• [62] Yang JP, Liu Y, Zhong W, Yu D, Wen LJ, Jin CS. Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma. Chin Med J (Engl) 2011;124:1055-60.
• [63] Jin X, Zhao Y, Qian J, Tang J, Zhan XD. [Aldehyde dehydrogenase 1 can be used as a new marker of cancer stem cells in laryngeal cancer cells in vitro]. Zhonghua Zhong Liu Za Zhi 2011;33:900-4. [Article in Chinese]
• [64] Martín M, Hinojar A, Cerezo L, García J, Lopez M, Prada J, et al. Aldehyde dehydrogenase isoform 1 (ALDH1) expression as a predictor of radiosensitivity in laryngeal cancer. Clin Transl Oncol 2016;18:825-30.
• [65] Luzar B, Poljak M, Marin IJ, Fischinger J, Gale N. Quantitative measurement of telomerase catalytic subunit (hTERT) mRNA in laryngeal squamous cell carcinomas. Anticancer Res 2001;21(6A):4011-5.
• [66] Chen SM, Tao ZZ, Hua QQ, Xiao BK, Xu Y, Wang Y, et al. Inhibition of telomerase activity in cancer cells using short hairpin RNA expression vectors. Cancer Invest 2007;25:691-8.
• [67] Liao Z, Huang C, Zhou F, Xiong J, Bao J, Zhang H, Sun W, Xie C, Zhou Y. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett 2009;283:20-8.
• [68] Wei G, Du Y, Yang C, Zhang X. [The expression and significance of integrin beta1 and focal adhesion kinase and its clinical value in laryngeal carcinoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22:1112-4. [Article in Chinese]